The latest data, presented at VIVA and The VEINS

Physicians and researchers present groundbreaking findings from late-breaking clinical trials, follow-up data from major randomized trials and registries, and first-in-man experiences with novel devices or drugs. Each presentation is followed by a discussion and Q&A with a panel of expert faculty.

Embargo Policy

VIVA and The VEINS embargo Late-Breaking Clinical Trial information from becoming public until after the commencement of the session as listed in the conference program or on No publication, exhibitor, or affiliated company may disseminate information until after the commencement of the Late-Breaking Clinical Trial session in which it is presented.

Submission Guidelines

A limited number of abstracts will be accepted for presentation. Please read the submission guidelines carefully before submitting your abstract for consideration.

The abstract submission deadline is Thursday, August 10 at 5pm PDT.

Abstracts must be submitted electronically via the official late-breaking abstract submission website. Research must be original and may not have been presented prior to the Late-Breaking Clinical Trial sessions at VIVA or The VEINS 2023.

Accepted late-breaking clinical trials will be presented:

  • Monday, October 30 (The VEINS)
  • Tuesday, October 31 (VIVA)
  • Wednesday, November 1 (VIVA)

Submissions should address areas of endovascular intervention and medicine and can report the results of basic science investigations as well as clinical or pre-clinical studies.

Abstracts must include:

  • Trial name
  • Purpose
  • Materials and methods
  • Results
  • Conclusion

The total abstract length may not exceed 2,500 characters, exclusive of title or figures. The following information must be provided upon submission:

  • Submitter name
  • Primary contact name
  • Organization/institution
  • Phone number
  • Email address
  • Names of authors
  • Name of who will present the abstract, if selected
    • Phone number
    • Email address
  • Name of the company or entity providing funding or research support
  • Six-word title for abstract presentation


Submitted abstracts will be reviewed after the August 10 deadline. Abstracts will be evaluated and scored based on the following criteria:

  • Interest to field
  • Research methods
  • Quality of data
  • Primary endpoint presented

Notice of acceptance or rejection will be sent the week of August 21. Subsequent communication will provide specifics about submitting the presentation and the date and time of the presentation.

The review committee may determine that your abstract may be more appropriate for a different session or conference than you originally submitted.

If you have questions please contact Brita Thorne via e-mail: